Hostname: page-component-7479d7b7d-m9pkr Total loading time: 0 Render date: 2024-07-10T22:19:07.693Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and Safety of N-3 Phosphatidylserine in Children with Attention Deficit and Hyperactivity Disorder (ADHD)

Published online by Cambridge University Press:  16 April 2020

I. Manor ,
S. Rozen ,
Y. Manor ,
D. Pelled  and
A. Weizman
I. Manor
Affiliation:
ADHD Unit, Geha Mental Health Center, Sackler Faculty of Medicine, Tel Aviv University, Petach-Tiqva, Israel
S. Rozen
Affiliation:
ADHD Unit, Geha Mental Health Center, Petach-Tikva, Israel
Y. Manor
Affiliation:
R&D Department, Enzymotec LTD, Migdal-HaEmeq, Israel
D. Pelled
Affiliation:
R&D Department, Enzymotec LTD, Migdal-HaEmeq, Israel
A. Weizman
Affiliation:
Research Unit, Geha Mental Health Center, 5 Felsenstein Medical Research Center, Beilinson Campus, Tel-Aviv University, Petach Tikva, Israel

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Attention-deficit/hyperactivity disorder (ADHD) encompasses a broad constellation of behavioral and learning problems. These patients are also characterized by low blood long-chain polyunsaturated fatty acid concentrations; however their supplementation effect on ADHD symptoms is not clear. It was recently (1) shown in children with inattention that consumption of n-3 phosphatidylserine (PS) for 3-mo favorably affected their visual sustained attention performance. We aimed to evaluate in children with ADHD the effect of n-3 PS on ADHD symptoms and wellbeing.

Methods:

In this 15-week, randomized, double-blind, placebo-controlled, parallel study the impact and tolerability of 150 mg b.i.d. n-3 PS were investigated in 200 children (6-13-y) with ADHD. Efficacy was assessed by teachers’ Conners Rating Scale (CRS) and strength and difficulties questionnaires (SDQ) - school version and clinicians who filled Clinical Global Impression of Improvement. Additional measures included parental rating of behavior (CRS and SDQ - home version) and wellbeing (Child Health questionnaire - Parental Form 50), and continuous performance test (Test of Variables of Attention). Safety evaluation included adverse event reports, vital signs, and parents’ Barkley’ side effects rating scale.

Results:

The interim results of the first group of children that were randomly assigned in a 2:1 ratio to n-3 PS or placebo will be presented.

Conclusions:

n-3 PS impact on ADHD symptoms at school and home as evaluated by teachers, clinicians, and parents will be discussed.

Acknowledgement:

This work was sponsored by Enzymotec LTD.

Type
S01-03
Information
European Psychiatry , Volume 24 , Issue S1: 17th EPA Congress - Lisbon, Portugal, January 2009, Abstract book , January 2009 , 24-E12
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.